Nhi Nguyen, Nasima Afzal, Mildred Min, Nabeel Ahmad, Laila Afzal, Waqas Burney, Cindy J Chambers, Raja K Sivamani
{"title":"一项前瞻性,双盲,随机头对头的临床试验,外用adapalinoid (adapalenate油基)与视黄醇。","authors":"Nhi Nguyen, Nasima Afzal, Mildred Min, Nabeel Ahmad, Laila Afzal, Waqas Burney, Cindy J Chambers, Raja K Sivamani","doi":"10.1002/ski2.469","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Retinoids, such as retinol, are widely investigated and utilized in skin care products as a treatment for photoaging but their use is limited by tolerability. Adapinoid (oleyl adapalenate, OA) is a novel third generation retinoid that is a pro-drug of adapalene, but there is little research on its effects on photoaging or its tolerability.</p><p><strong>Objectives: </strong>The purpose of this study is to compare the effects and tolerability of OA 0.5% to retinol 0.5% cream regarding visible signs of facial photoaging including facial wrinkles, fine lines and pigmentation.</p><p><strong>Methods: </strong>In this 12-week, double-blind, randomized clinical trial, 48 eligible participants were recruited and enroled from the Greater Sacramento region. The study consisted of a baseline and follow-up visits at weeks 4, 8 and 12. Participants were randomized to receive either topical OA 0.5% or retinol 0.5% for 12 weeks. The primary outcome was changes in the appearance of wrinkle severity at 12 weeks. Secondary outcome measures include changes in erythema, skin pigmentation, skin hydration and transepidermal water loss (TEWL).</p><p><strong>Results: </strong>OA improved wrinkle severity by 9.45% (<i>p</i> < 0.0001) at week 12, whereas retinol improved wrinkle severity by 4.11% (<i>p</i> < 0.001) compared to baseline. When comparing the two treatment groups at week 12, the OA group improved significantly more than the retinol group (<i>p</i> = 0.001). OA decreased pigment intensity at week 12 by 3.88% (<i>p</i> < 0.0001), whereas retinol decreased pigment intensity by 3.15% (<i>p</i> < 0.03) compared to baseline. OA-based improvement in pigment intensity at week 12 was not significantly different from retinol (<i>p</i> = 0.62). OA reduced facial erythema by 13.39% (<i>p</i> < 0.05) at week 12, whereas the retinol group did not have a significant change. OA use led to a 14.92% decrease in TEWL by week 12 (<i>p</i> = 0.07), whereas the retinol group had no significant change. OA was better tolerated than retinol when assessed at all follow-up visits.</p><p><strong>Conclusions: </strong>OA 0.5% is superior to retinol 0.5% in improving wrinkle severity and similar in improvement of pigment intensity. OA is better tolerated than retinol. Overall, the use of OA as a precursor to adapalene may be an effective method to improving the tolerability of retinoids while maintaining efficacy.</p><p><strong>Trial registration: </strong>This study was registered on www.clinicaltrials.gov (NCT05778760).</p>","PeriodicalId":74804,"journal":{"name":"Skin health and disease","volume":"4 6","pages":"e469"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11608876/pdf/","citationCount":"0","resultStr":"{\"title\":\"A prospective, double-blinded, randomized head-to-head clinical trial of topical adapinoid (oleyl adapalenate) versus retinol.\",\"authors\":\"Nhi Nguyen, Nasima Afzal, Mildred Min, Nabeel Ahmad, Laila Afzal, Waqas Burney, Cindy J Chambers, Raja K Sivamani\",\"doi\":\"10.1002/ski2.469\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Retinoids, such as retinol, are widely investigated and utilized in skin care products as a treatment for photoaging but their use is limited by tolerability. Adapinoid (oleyl adapalenate, OA) is a novel third generation retinoid that is a pro-drug of adapalene, but there is little research on its effects on photoaging or its tolerability.</p><p><strong>Objectives: </strong>The purpose of this study is to compare the effects and tolerability of OA 0.5% to retinol 0.5% cream regarding visible signs of facial photoaging including facial wrinkles, fine lines and pigmentation.</p><p><strong>Methods: </strong>In this 12-week, double-blind, randomized clinical trial, 48 eligible participants were recruited and enroled from the Greater Sacramento region. The study consisted of a baseline and follow-up visits at weeks 4, 8 and 12. Participants were randomized to receive either topical OA 0.5% or retinol 0.5% for 12 weeks. The primary outcome was changes in the appearance of wrinkle severity at 12 weeks. Secondary outcome measures include changes in erythema, skin pigmentation, skin hydration and transepidermal water loss (TEWL).</p><p><strong>Results: </strong>OA improved wrinkle severity by 9.45% (<i>p</i> < 0.0001) at week 12, whereas retinol improved wrinkle severity by 4.11% (<i>p</i> < 0.001) compared to baseline. When comparing the two treatment groups at week 12, the OA group improved significantly more than the retinol group (<i>p</i> = 0.001). OA decreased pigment intensity at week 12 by 3.88% (<i>p</i> < 0.0001), whereas retinol decreased pigment intensity by 3.15% (<i>p</i> < 0.03) compared to baseline. OA-based improvement in pigment intensity at week 12 was not significantly different from retinol (<i>p</i> = 0.62). OA reduced facial erythema by 13.39% (<i>p</i> < 0.05) at week 12, whereas the retinol group did not have a significant change. OA use led to a 14.92% decrease in TEWL by week 12 (<i>p</i> = 0.07), whereas the retinol group had no significant change. OA was better tolerated than retinol when assessed at all follow-up visits.</p><p><strong>Conclusions: </strong>OA 0.5% is superior to retinol 0.5% in improving wrinkle severity and similar in improvement of pigment intensity. OA is better tolerated than retinol. Overall, the use of OA as a precursor to adapalene may be an effective method to improving the tolerability of retinoids while maintaining efficacy.</p><p><strong>Trial registration: </strong>This study was registered on www.clinicaltrials.gov (NCT05778760).</p>\",\"PeriodicalId\":74804,\"journal\":{\"name\":\"Skin health and disease\",\"volume\":\"4 6\",\"pages\":\"e469\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11608876/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Skin health and disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/ski2.469\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Skin health and disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/ski2.469","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
背景:类维生素a,如视黄醇,被广泛研究并用于护肤品中作为光老化的治疗,但其使用受到耐受性的限制。Adapinoid(油基adapalenate, OA)是一种新型的第三代类维生素a,是阿达帕烯的前药,但对其抗光老化和耐受性的研究很少。目的:本研究的目的是比较0.5% OA和0.5%视黄醇乳膏对面部光老化的明显迹象(包括面部皱纹、细纹和色素沉着)的影响和耐受性。方法:在这项为期12周的双盲随机临床试验中,从大萨克拉门托地区招募了48名符合条件的参与者。该研究包括基线和第4、8和12周的随访。参与者随机接受局部0.5% OA或0.5%视黄醇治疗12周。主要结果是12周时皱纹严重程度的变化。次要结局指标包括红斑、皮肤色素沉着、皮肤水化和经皮失水(TEWL)的变化。结果:OA改善皱纹严重程度9.45% (p p p = 0.001)。OA使第12周色素强度降低3.88% (p p p = 0.62)。OA组面部红斑减少13.39% (p p = 0.07),而视黄醇组无显著变化。在所有随访评估中,OA的耐受性优于视黄醇。结论:0.5% OA改善皱纹严重度的效果优于0.5%视黄醇,改善色素强度的效果相似。OA比视黄醇耐受性更好。总之,使用OA作为阿达帕烯的前体可能是提高类维生素a耐受性同时保持疗效的有效方法。试验注册:本研究在www.clinicaltrials.gov (NCT05778760)上注册。
A prospective, double-blinded, randomized head-to-head clinical trial of topical adapinoid (oleyl adapalenate) versus retinol.
Background: Retinoids, such as retinol, are widely investigated and utilized in skin care products as a treatment for photoaging but their use is limited by tolerability. Adapinoid (oleyl adapalenate, OA) is a novel third generation retinoid that is a pro-drug of adapalene, but there is little research on its effects on photoaging or its tolerability.
Objectives: The purpose of this study is to compare the effects and tolerability of OA 0.5% to retinol 0.5% cream regarding visible signs of facial photoaging including facial wrinkles, fine lines and pigmentation.
Methods: In this 12-week, double-blind, randomized clinical trial, 48 eligible participants were recruited and enroled from the Greater Sacramento region. The study consisted of a baseline and follow-up visits at weeks 4, 8 and 12. Participants were randomized to receive either topical OA 0.5% or retinol 0.5% for 12 weeks. The primary outcome was changes in the appearance of wrinkle severity at 12 weeks. Secondary outcome measures include changes in erythema, skin pigmentation, skin hydration and transepidermal water loss (TEWL).
Results: OA improved wrinkle severity by 9.45% (p < 0.0001) at week 12, whereas retinol improved wrinkle severity by 4.11% (p < 0.001) compared to baseline. When comparing the two treatment groups at week 12, the OA group improved significantly more than the retinol group (p = 0.001). OA decreased pigment intensity at week 12 by 3.88% (p < 0.0001), whereas retinol decreased pigment intensity by 3.15% (p < 0.03) compared to baseline. OA-based improvement in pigment intensity at week 12 was not significantly different from retinol (p = 0.62). OA reduced facial erythema by 13.39% (p < 0.05) at week 12, whereas the retinol group did not have a significant change. OA use led to a 14.92% decrease in TEWL by week 12 (p = 0.07), whereas the retinol group had no significant change. OA was better tolerated than retinol when assessed at all follow-up visits.
Conclusions: OA 0.5% is superior to retinol 0.5% in improving wrinkle severity and similar in improvement of pigment intensity. OA is better tolerated than retinol. Overall, the use of OA as a precursor to adapalene may be an effective method to improving the tolerability of retinoids while maintaining efficacy.
Trial registration: This study was registered on www.clinicaltrials.gov (NCT05778760).